GSK at Oncology Medical Congresses 2024
GSK will unveil data from its oncology portfolio through 25 presentations at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting and 18 presentations at the European Hematology Association (EHA) 2024 Hybrid Congress. These data include compelling and highly anticipated research GSK is conducting to develop new treatment options that improve patient outcomes in complex and difficult-to-treat blood, gynaecologic and other solid tumour cancers.
This research reflects our unwavering commitment to maximising the potential of our approved and investigational therapies, alone and in combination, to improve patient lives and get ahead of disease together.
Applying precision medicine in oncology
Recent advancements in technology have allowed for the development and implementation of precision medicine practices, which can improve outcomes for those living with cancer by helping match the right patient with the right medicine at the right dose and time in their cancer journey.
Learn more from Anne-Marie Martin, GSK’s Global Head of Precision Medicine, on the research and development of precision oncology and the future of cancer treatment.
Understanding the patient experience
Patients inspire our commitment to developing new therapies for complex and difficult-to-treat cancers. Watch to learn more about their stories and unique experiences living with haematologic and gynaecologic malignancies.
Data visualisation booth from ASCO®
We believe innovation starts when we stop to listen. We created a simple tool to include you in the conversation about how we innovate and collaborate in oncology to get ahead of disease together. Join us by meeting rooms at Booth #22023 to make your voice heard.
The content below is dynamic and will be updated with results periodically to reflect answers on-site.
-
Oncologist
37% -
Pharmaceuticals (R&D)
15% -
Pharmaceuticals (Sales)
4%
-
Pharmaceuticals (Other)
26% -
Academia
9% -
Patient advocate
8%
-
Focus on precision medicine and personalised treatment options
41% -
Advance cancer prevention and early detection
32% -
Foster greater access to clinical trials
14%
-
Improve access to genetic testing and treatments
8% -
Harness advanced tech to improve patient experience
5%
-
Genomics and next generation sequencing
28% -
Combination therapies
19% -
Biomarker development
27%
-
Cell therapy advancements
8% -
Tumour microenvironment research
9% -
Transformative IO (immuno-oncology)
9%
-
Flexible sharing and use of advanced technologies
35% -
Increased access to data
40%
-
Development scalability
9% -
Connecting leading talent and expertise
16%
Go behind the science
Discover how we’re uniting technology, science, and talent to get ahead of cancer.
